Giant cell arteritis therapy options widen past corticosteroids
Tocilizumab maturity, secukinumab pivotal data, and emerging mechanism-targeted programs are reshaping giant cell arteritis management.
Giant cell arteritis (temporal arteritis) has been a long-course-corticosteroid category for decades. Tocilizumab (IL-6 receptor antagonist) has approval as a steroid-sparing agent and is now widely used; secukinumab has reported positive pivotal data in giant cell arteritis adding an IL-17 mechanism class option; abatacept and JAK pathway programs are in late-stage trials. The category has gone from corticosteroid-only to a real steroid-sparing prescribing tier in three years.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- SnapshotLupus nephritis therapy reference (2026)
- ExplainedWhat is lupus nephritis?